CLINICAL TRIALS PROFILE FOR DUPILUMAB

All Clinical Trials for dupilumab

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01312961 ↗	Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma	Completed	Regeneron Pharmaceuticals	Phase 2	2011-03-01	Primary Objective: To investigate the effects of Dupilumab (SAR231893/REGN668) administered subcutaneously (SC) once weekly (qw) for 12 weeks as compared to placebo on reducing the incidence of asthma exacerbation in participants with persistent moderate to severe eosinophilic asthma. Secondary Objectives: - To assess the safety and tolerability of Dupilumab administered SC qw for 12 weeks in participants with persistent moderate to severe eosinophilic asthma. - To assess Dupilumab serum concentrations following qw SC dosing for 12 weeks in participants with persistent moderate to severe eosinophilic asthma.
NCT01312961 ↗	Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma	Completed	Sanofi	Phase 2	2011-03-01	Primary Objective: To investigate the effects of Dupilumab (SAR231893/REGN668) administered subcutaneously (SC) once weekly (qw) for 12 weeks as compared to placebo on reducing the incidence of asthma exacerbation in participants with persistent moderate to severe eosinophilic asthma. Secondary Objectives: - To assess the safety and tolerability of Dupilumab administered SC qw for 12 weeks in participants with persistent moderate to severe eosinophilic asthma. - To assess Dupilumab serum concentrations following qw SC dosing for 12 weeks in participants with persistent moderate to severe eosinophilic asthma.
NCT01385657 ↗	Safety and Tolerability of Dupilumab in Participants With Moderate to Severe Atopic Dermatitis	Completed	Sanofi	Phase 1	2011-07-31	The purpose of this study is to assess the safety and tolerability of repeated subcutaneous (SC) doses of Dupilumab in participants with moderate-to-severe atopic dermatitis (AD).
NCT01385657 ↗	Safety and Tolerability of Dupilumab in Participants With Moderate to Severe Atopic Dermatitis	Completed	Regeneron Pharmaceuticals	Phase 1	2011-07-31	The purpose of this study is to assess the safety and tolerability of repeated subcutaneous (SC) doses of Dupilumab in participants with moderate-to-severe atopic dermatitis (AD).
NCT01548404 ↗	Study of Dupilumab in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis	Completed	Sanofi	Phase 2	2012-04-01	The primary objective was to assess the clinical efficacy of repeated subcutaneous (SC) doses of Dupilumab in adult participants with moderate-to-severe atopic dermatitis (AD).
NCT01548404 ↗	Study of Dupilumab in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis	Completed	Regeneron Pharmaceuticals	Phase 2	2012-04-01	The primary objective was to assess the clinical efficacy of repeated subcutaneous (SC) doses of Dupilumab in adult participants with moderate-to-severe atopic dermatitis (AD).
NCT01639040 ↗	Study to Assess the Safety of Dupilumab (REGN668/SAR231893) Administered Concomitantly With Topical Corticosteroids (TCS) in Patients With Moderate-to-severe Atopic Dermatitis (AD)	Completed	Sanofi	Phase 2	2012-07-01	The purpose of this study was to assess the safety of Dupilumab administered concomitantly with topical corticosteroids (TCS) in patients with moderate-to-severe atopic dermatitis (AD).

Clinical Trial Conditions for dupilumab

Condition Name

Condition Name for dupilumab
Intervention	Trials
Atopic Dermatitis	40
Asthma	21
Dermatitis, Atopic	8
Nasal Polyps	5

Condition MeSH

Condition MeSH for dupilumab
Intervention	Trials
Dermatitis	59
Dermatitis, Atopic	55
Eczema	53
Asthma	24

Clinical Trial Locations for dupilumab

Trials by Country

Trials by Country for dupilumab
Location	Trials
United States	941
Canada	118
Japan	114
Germany	86
Poland	85

Trials by US State

Trials by US State for dupilumab
Location	Trials
California	58
Florida	44
New York	43
Texas	42
Pennsylvania	39

Clinical Trial Progress for dupilumab

Clinical Trial Phase

Clinical Trial Phase for dupilumab
Clinical Trial Phase	Trials
Phase 4	38
Phase 3	42
Phase 2/Phase 3	5

Clinical Trial Status

Clinical Trial Status for dupilumab
Clinical Trial Phase	Trials
Recruiting	52
Completed	41
Not yet recruiting	31

Clinical Trial Sponsors for dupilumab

Sponsor Name

Sponsor Name for dupilumab
Sponsor	Trials
Regeneron Pharmaceuticals	92
Sanofi	78
National Institute of Allergy and Infectious Diseases (NIAID)	8

Sponsor Type

Sponsor Type for dupilumab
Sponsor	Trials
Industry	187
Other	74
NIH	9